VTAE 17.85 Vitae Pharmaceuticals Inc $VTAE Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 2:22 PM

VTAE 17.85 Vitae Pharmaceuticals Inc $VTAE Hit a 52 week high of 18.30 Closing the day 09:45 at 17.85 +0.64 +3.72% With a day low of 17.00 and a total volume of 54,801.

VTAE Recent Posts: http://investorshangout.com/Vitae-Pharmaceuti...TAE-90576/

VTAE Vitae Pharmaceuticals Inc Recent Headline News

Vitae Pharmaceuticals EPS of -$1.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:15PM CST

VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results
GlobeNewswire - Wed Nov 12, 3:06PM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the third quarter ended September 30, 2014.
VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:00AM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:45 p.m. EST in New York City.
VTAE: 15.86 (-1.35)

Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.86 (-1.35), LLY: 67.57 (+0.17), CNCE: 13.49 (+0.66), OPK: 8.36 (-0.01), AZN: 74.53 (+0.27), ALXN: 192.68 (-1.01), ICPT: 162.72 (-0.24), NPSP: 29.88 (+0.71), XLRN: 38.03 (+4.24)

Vitae Pharma reports November 12
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:04AM CST

VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
GlobeNewswire - Wed Nov 05, 5:30PM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at 4:30 p.m. EST to discuss third quarter 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
VTAE: 15.86 (-1.35)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.81 (-0.01), AMKR: 6.44 (unch), VTAE: 15.86 (-1.35), ASTI: 2.17 (+0.15), CLF: 10.58 (-0.13), LMNX: 18.22 (-0.29), IDTI: 17.64 (-0.11), HNR: 2.93 (-0.06), VDSI: 27.21 (+0.80), DCO: 24.82 (-0.32), MDCO: 24.54 (-0.73), SCYX: 9.30 (-0.18), VGGL: 3.12 (-0.38), RCPT: 111.30 (-0.13), IBIO: 1.12 (+0.01), SNY: 46.52 (-0.04), TWTR: 41.01 (-1.53), DPW: 1.66 (+0.03), MERU: 3.91 (-0.02), SANM: 24.83 (-0.23)

Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 15.86 (-1.35), AAPL: 112.61 (+1.36), ALXA: 1.61 (+0.01)

Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
GlobeNewswire - Mon Oct 27, 3:10PM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.
VTAE: 15.86 (-1.35)

Vitae Pharma up premarket on Phase 1 trial results
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 8:31AM CDT

VTAE: 15.86 (-1.35)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 8:15AM CDT

AMZN: 316.09 (+4.58), SYNA: 62.00 (-1.19), FNFG: 7.75 (-0.03), VTAE: 15.86 (-1.35), VSR: 2.97 (-0.02), RMTI: 11.13 (-0.11), DRIV: 24.70 (+0.17), MXWL: 10.96 (+0.04), OXGN: 1.76 (+0.01), GIMO: 14.48 (-0.30), P: 18.53 (-0.26), APT: 2.85 (-0.15), BJRI: 46.36 (-0.99), LAKE: 11.40 (-0.84), IBIO: 1.12 (+0.01), KLAC: 79.57 (-0.16), DRYS: 1.39 (-0.04)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:42PM CDT

MXWL: 10.96 (+0.04), AMZN: 316.09 (+4.58), GIMO: 14.48 (-0.30), UFCS: 29.30 (-0.65), ABG: 74.30 (-1.70), P: 18.53 (-0.26), SYNA: 62.00 (-1.19), RUBI: 13.14 (+0.05), VTAE: 15.86 (-1.35), KLAC: 79.57 (-0.16)

Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
GlobeNewswire - Thu Oct 23, 3:10PM CDT
-- BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels
VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $48.4 million. As previously reported, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 15.86 (-1.35)

CyberArk Soars 60% To Lead Post-IPO Trading Debuts
at Investor's Business Daily - Wed Sep 24, 2:41PM CDT
CyberArk Software soared 60% in first-day trading after its IPO priced above views, leading a group of new issues making their debuts Wednesday. The maker of security software designed to thwart cyberattacks, CyberArk Software (CYBR) priced 5.36...
ICL: 7.03 (-0.06), MDLY: 16.27 (-0.13), SFS: 14.27 (-0.31), JPM: 60.14 (-0.42), CYBR: 41.62 (+7.92), VTAE: 15.86 (-1.35), CFG: 23.66 (-0.20), RBS: 11.72 (-0.10), AAPL: 112.61 (+1.36), BABA: 115.20 (-3.00)

Vitae Pharmaceuticals Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Sep 24, 8:25AM CDT
Vitae Pharmaceuticals, Inc., a clinical stage biotechnology company, today announced the pricing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on September 24, 2014 under the ticker symbol "VTAE." In addition, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 15.86 (-1.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CORE Embraces Tech to Boost Organ Donation Efforts

Innovation Meets Organ Donation Out of all the business moves you hear about, this one rings loud because it doesn’t just move the needle on a spreadsheet—it moves the needle on life or death. The Center for Organ Recovery & Education (CORE) is stepping into the future with a high-tech touch to enhance their lifesaving mission. Partnering with InVita Healthcare...

transcosmos & Metaverse Creators to Boost VRChat Content

Charting the Course for Global VR Expansion transcosmos and Metaverse Creators are throwing down the gauntlet to the barriers between Japanese VR magic and the global market. They're teaming up to sling 3D content from creators in Japan straight to users worldwide via Geek Jack, a cross-border e-commerce bridge built for entertainment. You can't deny it—VRChat's allure...

CTCA Tackles Trust Issues in $B-illion Card Market

Gaps in a Booming Industry Trading cards might sound like kid stuff, but don’t be fooled—there's billions riding on paper and ink these days. Yet, a dark cloud hovers over the trading card scene, where questions of transparency and accountability loom large. Digital repacks and those dicey randomized packs have folks questioning what’s in the mix: Is it a safe bet...

MTB Auction Spotlights 61 Lots of Key CNC Equipment

A Windfall of Opportunities for Equipment Buyers The hum of CNC machines, the clang of fabrication tools—it's the symphony of progress echoing from workshops around the world. Machine Tool Bids (MTB) is rolling out the red carpet for manufacturing enthusiasts with its October 28 auction. How often do you get a shot at 61 lots of top-tier metalworking equipment at your...

Gargle App Elevates Dental Marketing Transparency, ROI Focus

Dentists Finally See the Whole Picture with Gargle's App Out in Lehi, Utah, there's a little tech shakeup courtesy of Gargle—a name some might squint at if they haven't been following dental-focused digital marketing. Now, with their latest move, the Gargle App, we're talking about pulling back the curtain and giving dental practices a clear view of their marketing...

Yuchai Eyes African Market Expansion with Strategic Visits

Yuchai's Bold Move into Africa There's something gutsy about a company that doesn't just sit on its achievements but heads out into new territories. China Yuchai International (NYSE: CYD), a big player in powertrain solutions, recently embarked on a strategic tour across the African continent, a move that could well shape their future market playbook. East Africa:...

Navigating Market Uncertainty with Financial Planning

Staying Calm Amid Market Chaos The market's like a roller coaster more often than not, and when headlines scream panic, even the most seasoned of us can begin to doubt our strategies. Jennifer Prosise from The Voyager Group, Ltd., in Joliet, IL, calls out this high-stakes game in HelloNation, emphasizing how financial planning serves as our anchor in the stormy seas of...

Exploring Manual Lymphatic Massage: Key Benefits & Insights

The Surge in Popularity of Manual Lymphatic Massage There's a whole lotta buzz around manual lymphatic drainage (MLD) these days, and folks want to know if all that hype's got any juice. During National Massage Therapy Awareness Week, the American Massage Therapy Association (AMTA) lent a hand by spotlighting what the latest research has to say about this specialized...

Americans' Faith in Democracy Hits New Lows

By Hannah Lewis Updated Oct 27, 2026 Category News Views 111

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...

Heart Attack vs. Cardiac Arrest: Know the Differences

Spotting the Crisis: Heart Attack or Cardiac Arrest? When your heart’s in trouble, knowing whether it’s a heart attack or cardiac arrest isn’t just some medical trivia—it could save a life. According to healthcare whiz Justin Doss from Beaumont, Texas, this difference can be the thin line between life and a dire outcome. What's the Deal with These Heart Events?...